Jeff Johnson
Stock Analyst at Baird
(4.66)
# 184
Out of 4,712 analysts
138
Total ratings
57.61%
Success rate
32.77%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PDCO Patterson Companies | Maintains: Neutral | $25 → $31 | $30.80 | +0.65% | 7 | Dec 12, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $39 → $37 | $35.84 | +3.24% | 14 | Nov 7, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $22 | $19.11 | +15.12% | 7 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $358.72 | +12.90% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $208.49 | +32.38% | 18 | Oct 24, 2024 | |
| COO The Cooper Companies | Maintains: Outperform | $118 → $125 | $90.66 | +37.88% | 15 | Aug 29, 2024 | |
| ALC Alcon | Maintains: Outperform | $104 → $110 | $83.45 | +31.82% | 8 | Aug 22, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $155 → $145 | $104.46 | +38.81% | 13 | Aug 8, 2024 | |
| HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $68.55 | +19.62% | 9 | Aug 7, 2024 | |
| DXCM DexCom | Maintains: Neutral | $80 → $82 | $78.50 | +4.46% | 12 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $256.85 | -7.34% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $44.30 | +58.01% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $16.96 | +259.67% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $18.75 | +257.33% | 6 | Feb 18, 2022 |
Patterson Companies
Dec 12, 2024
Maintains: Neutral
Price Target: $25 → $31
Current: $30.80
Upside: +0.65%
Tandem Diabetes Care
Nov 7, 2024
Maintains: Neutral
Price Target: $39 → $37
Current: $35.84
Upside: +3.24%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $17 → $22
Current: $19.11
Upside: +15.12%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $358.72
Upside: +12.90%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $208.49
Upside: +32.38%
The Cooper Companies
Aug 29, 2024
Maintains: Outperform
Price Target: $118 → $125
Current: $90.66
Upside: +37.88%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $104 → $110
Current: $83.45
Upside: +31.82%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Outperform
Price Target: $155 → $145
Current: $104.46
Upside: +38.81%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $68.55
Upside: +19.62%
DexCom
Aug 5, 2024
Maintains: Neutral
Price Target: $80 → $82
Current: $78.50
Upside: +4.46%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $256.85
Upside: -7.34%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $44.30
Upside: +58.01%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $16.96
Upside: +259.67%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $18.75
Upside: +257.33%